Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avid Radiopharmaceuticals
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Probable AD according to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
Mild/moderate dementia as evidenced by a mini mental state exam (MMSE) score ranging from 10 to 24, boundaries included, at screening
History of cognitive decline had been gradual in onset and progressive over a period of at least 6 months
No evidence of significant cognitive impairment by history and psychometric testing
MMSE of 29 or higher
You may not be if
Neurodegenerative disorders other than AD
Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain infection, brain cancer, endocrine disease, or mental retardation
Clinically significant infarct or possible multi-infarct dementia as defined by the NINCDS criteria
Evidence on screening MRI or other biomarker that suggests alternate etiology for cognitive deficit (for healthy controls, evidence suggesting the presence of AD pathology)
Clinically significant psychiatric disease
History of epilepsy or convulsions
Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
Current clinically significant cardiovascular disease
Received investigational medication within the last 30 days
Clareo Health | A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
